# PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

> **NCT07188610** · PHASE2 · RECRUITING · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma

## Interventions

- **BIOLOGICAL:** T cell injection targeting CD7 chimeric antigen receptor

## Key facts

- **NCT ID:** NCT07188610
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2026-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07188610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07188610, "PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07188610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*